Angiotensin‐receptor blockers and diuretics—Advantages of combination

References

• Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense H-W, Joffres M, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289: 2363–2369.
   Google Scholar
• EUROASPIRE II Study Group, Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J. 2001;22:554–572.
   PubMed Web of Science ®Google Scholar
• Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199–206.
   PubMed Web of Science ®Google Scholar
• Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: A cohort study. Lancet. 2001;358:1682–1686.
   Google Scholar
• Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002;287:1003–1010.
   Google Scholar
• Guidelines Committee,2003 European Society ofHypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011–1053.
   Google Scholar
• Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al., National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureNational High Blood Pressure Education Program Coordinating Committee, Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252.
   Google Scholar
• Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755–1762.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–713.
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–2997.
   Google Scholar
• Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al., VALUE trial group, Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet. 2004;363:2022–2031.
   Google Scholar
• Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al., SCOPE Study Group, The study on cognition and prognosis in the elderly (SCOPE): Principal results of a randomised double-blind intervention trial. J Hypertens. 2003;21:875–886.
   Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al., LIFE Study Group, Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:995–1003.
   Google Scholar
• Primatesta P, Brookes M, Poulter NR. Improved hyperten-sion management and control: Results from the health survey for England 1998. Hypertension. 2001;38: 827–832.
   Google Scholar
• Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents. A network meta-analysis. JAMA. 2003;289:2534–2544.
   Google Scholar
• Weber MA, Drayer JIM, Rev A, Laragh JH. Disparate patterns of aldosterone response during diuretic treatment of hypertension. Ann Intern Med. 1977;87:558–563.
   PubMed Web of Science ®Google Scholar
• de Gasparo M, Levens N. Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotensin-converting enzyme? Pharmacol Toxicol. 1998;82:257–271.
   Google Scholar
• Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Amer P, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group, The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–878.
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Aurup P, Edelman J, et al., LIFE (Losartan Intervention for Endpoint Reduction) Study Group, Effects of losartan on cardiovas-cular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: A Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA. 2002;288:1491–1498.
   Google Scholar
• Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang YT, et al., Val-HeFT Heart Failure Trial Investigators, Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol. 2002;40:970–975.
   Google Scholar
• Palatini P, Malacco E, Di SS, Carretta R, Dorigatti F, Bertocchi F, et al. Trough:peak ratio and smoothness index in the evaluation of 24-h blood pressure control in hypertension: A comparative study between valsartan/hydrochlorothiazide combination and amlodipine. Eur J Chin Pharmacol. 2002;57:765–770.
   Google Scholar
• Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363:2049–2051.
   PubMed Web of Science ®Google Scholar
• Wang JG, Staessen JA. The benefit of treating isolated systolic hypertension. Curr Hypertens Rep. 2001;3:333–339.
   Google Scholar
• Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation. 2001;103:1245–1249.
   PubMed Web of Science ®Google Scholar
• Ramsay L, Williams B, Johnston G, MacGregor G, Poston L, Potter J, et al. British Hypertension Society Guidelines for Hypertension Management 1999: Summary. BMJ. 1999;319:630–635.
   PubMed Web of Science ®Google Scholar
• Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001;345:479–486.
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, Roccella EJ, Levy D. Differential control of systolic and diastolic blood pressure: Factors associated with lack of blood pressure control in the community. Hypertension. 2000;36:594–599.
   Google Scholar
• Brown MJ, Cruickshank JK, Dominiczak AF, MacGregor GA, Poulter NR, Russell GI, et al., Executive Committee, British Hypertension Society, Better blood pressure control: How to combine drugs. J Hum Hypertens. 2003;17:81–86.
   Google Scholar
• MaIlion JM, Carretta R, Trenkwalder P, Martinez JF, Tykarski A, Teitelbaum I, et al., Co-Diovan Study Group, Valsartan/hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. Blood Press. 2003;12 Suppl 1:36–43.
   Google Scholar
• Malacco E, Van N, Capuano V, Spagnuolo V, Borgnino C, Palatini P, Val-Syst study, A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: The Val-Syst study. Chin Ther. 2003;25:2765–2780.
   Google Scholar
• Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316:823–828.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association, Hypertension management in adults with diabetes. Diabetes Care. 2004;27 Suppl 1:S65–S67.
   Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al., RENAAL Study Investigators, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345: 861–869.
   Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al., Collaborative Study Group, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345: 851–860.
   Google Scholar
• Viberti G, Wheeldon NM, MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators, Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation. 2002;106:672–678.
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43:963–969.
   PubMed Web of Science ®Google Scholar
• Aguilar D, Solomon SD, Kober L, Rouleau JL, Skali H, McMurray JJ, et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: The Valsartan in Acute Myocardial Infarction (VALIANT) Trial. Circulation. 2004;110:1572–1578.
   PubMed Web of Science ®Google Scholar
• Mayet J, Shahi M, Foale RA, Poulter NR, Sever PS, Thom SAM. Racial differences in cardiac structure and function in essential hypertension. BMJ. 1994;308:1011–1014.
   Google Scholar
• Agyemang C, Bhopal R. Is the blood pressure of people from African origin adults in the UK higher or lower than that in European origin white people? A review of cross-sectional data. J Hum Hypertens. 2003;17:523–534.
   PubMed Web of Science ®Google Scholar
• Douglas JG, Bakris GL, Epstein M, Ferdinand KC, Ferrario C, Flack JM, et al., Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks, Management of high blood pressure in African Americans: Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003;163:525–541.
   Google Scholar
• Weir MR, Smith DHG, Neutel JM, Bedigian MP. Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: Relation to salt intake. Am J Hypertens. 2001;14:665–671.
   PubMedGoogle Scholar
• Powers DR, Wallin JD. End-stage renal disease in specific ethnic and racial groups: Risk factors and benefits of antihypertensive therapy. Arch Int Med. 1998;158:793–800.
   PubMed Web of Science ®Google Scholar
• Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al., African American Study of Kidney Disease and Hypertension Study Group, Effect of blood pressure lowering and antihypertensive drug class on progres-sion of hypertensive kidney disease: Results from the AASK trial. JANIA. 2002;288:2421–2431.
   Google Scholar